Teenagers from 15 Should Be Given MenB Vaccine, Say UK Experts After Kent Outbreak

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has reversed its advice on the meningitis B (MenB) vaccine for teenagers. Following a recent outbreak in Kent that claimed two lives, experts now recommend that all 15-year-olds be offered a free MenB vaccination.

This change of heart is long overdue and raises questions about how public health priorities have been managed. During the outbreak, parents were forced to purchase the vaccine privately for their teenagers, highlighting a glaring gap in the UK’s vaccination strategy. Despite being aware of the risks, authorities had previously deemed it not necessary or cost-effective to offer this protection to teens.

The JCVI’s decision is an admission that they underestimated the vulnerability of young people to MenB infections. Families like Aaron Mills’, whose son tragically lost his life to the disease despite being vaccinated against other strains of meningitis, have tirelessly advocated for change. Anthony Mills’ determination has undoubtedly played a crucial role in convincing the JCVI to amend its guidance.

The irony is that babies have been receiving the MenB vaccine since 2015 as part of their routine immunization program, yet those aged between 11 and 15 have been left exposed to this deadly disease. The JCVI now recommends two doses for teens at age 15, citing recent evidence that they are more likely to catch and fall ill from MenB due to their socially active lifestyles.

The UK government must allocate the necessary resources to provide free MenB jabs for all 15-year-olds. Anything less would be a dereliction of duty, particularly given the devastating consequences of meningitis infections, which can lead to life-changing disabilities such as amputations, hearing loss, and brain damage.

Pharmacies are already gearing up to offer this protection during the upcoming university intake, demonstrating that there is no shortage of infrastructure or willingness to deliver vaccines. However, a comprehensive national strategy prioritizing public health over bureaucratic red tape and cost-cutting measures is needed.

As Becca Heritage notes, young people’s lives are at stake here, and we can’t afford to wait any longer for action. The JCVI’s U-turn on MenB vaccination is a wake-up call for policymakers to re-examine public health priorities and ensure that vulnerable populations are protected from this disease.

The future of UK healthcare hangs in the balance, but one thing is certain – we’ve been given a second chance to get it right. Will we seize this opportunity, or will we continue down the path of complacency and delay? The clock is ticking.